This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
MedImmune, LLC
MedImmune, LLC, a subsidiary of AstraZeneca, is a leading biotechnology company headquartered in the United States. Founded in 1988, MedImmune has established itself as a key player in the biopharmaceutical industry, focusing on the development of innovative therapies for respiratory, oncology, and infectious diseases. With major operational regions across North America and Europe, MedImmune is renowned for its pioneering work in monoclonal antibodies and biologics. The company’s flagship products, including Synagis and FluMist, are distinguished by their unique mechanisms of action and significant clinical impact. MedImmune's commitment to research and development has positioned it as a market leader, achieving notable milestones such as the successful launch of groundbreaking therapies that address unmet medical needs. Through its dedication to advancing science and improving patient outcomes, MedImmune continues to shape the future of healthcare.
DitchCarbon Score
How does MedImmune, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MedImmune, LLC's score of 95 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MedImmune, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of AstraZeneca PLC, which means that its climate commitments and emissions data are inherited from its parent organisation. AstraZeneca has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are part of a broader strategy to achieve net-zero emissions by 2025 for its own operations (Scope 1 and 2) and by 2030 for its value chain (Scope 3). MedImmune, as part of AstraZeneca, aligns with these initiatives, although specific reduction targets for MedImmune itself have not been disclosed. The company participates in various climate initiatives cascaded from AstraZeneca, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on sourcing 100% renewable electricity. These commitments reflect a strong dedication to addressing climate change and reducing carbon footprints within the biopharmaceutical industry. While specific emissions figures for MedImmune are not available, the overarching goals set by AstraZeneca indicate a proactive approach to sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MedImmune, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
